Related references
Note: Only part of the references are listed.Efficacy and safety of inhaled once-daily low-dose indacaterol acetate/mometasone furoate in patients with inadequately controlled asthma: Phase III randomised QUARTZ study findings
Oliver Kornmann et al.
RESPIRATORY MEDICINE (2020)
Improved confidence intervals for a difference of two cause-specific cumulative incidence functions estimated in the presence of competing risks and random censoring
Emil Scosyrev
BIOMETRICAL JOURNAL (2020)
Fixed-dose combination of indacaterol/glycopyrronium/mometasone furoate once-daily versus salmeterol/fluticasone twice-daily plus tiotropium once-daily in patients with uncontrolled asthma: A randomised, Phase IIIb, non-inferiority study (ARGON)
Christian Gessner et al.
RESPIRATORY MEDICINE (2020)
Once-daily, single-inhaler mometasone–indacaterol–glycopyrronium versus mometasone–indacaterol or twice-daily fluticasone–salmeterol in patients with inadequately controlled asthma (IRIDIUM): a randomised, double-blind, controlled phase 3 study
Huib A M Kerstjens et al.
Lancet Respiratory Medicine (2020)
Effect of Aclidinium Bromide on Major Cardiovascular Events and Exacerbations in High-Risk Patients With Chronic Obstructive Pulmonary Disease The ASCENT-COPD Randomized Clinical Trial
Robert A. Wise et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2019)
Serious asthma events with mometasone furoate plus formoterol compared with mometasone furoate
Cindy L. J. Weinstein et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2019)
In COPD, new use of long-acting bronchodilators was linked to CV events at ≤ 30 days, but not > 30 days
Matthew B. Stanbrook
ANNALS OF INTERNAL MEDICINE (2018)
Combined Analysis of Asthma Safety Trials of Long-Acting beta(2)-Agonists
William W. Busse et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Once-Daily Single-Inhaler Triple versus Dual Therapy in Patients with COPD
David A. Lipson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Association of Cardiovascular Risk With Inhaled Long-Acting Bronchodilators in Patients With Chronic Obstructive Pulmonary Disease A Nested Case-Control Study
Meng-Ting Wang et al.
JAMA INTERNAL MEDICINE (2018)
Tiotropium and olodaterol in the prevention of chronic obstructive pulmonary disease exacerbations (DYNAGITO): a double-blind, randomised, parallel-group, active-controlled trial
Peter M. A. Calverley et al.
LANCET RESPIRATORY MEDICINE (2018)
Risk of Severe Cardiovascular Events From Add-On Tiotropium in Chronic Obstructive Pulmonary Disease
Jun-Ting Liou et al.
MAYO CLINIC PROCEEDINGS (2018)
Concurrent use of long-acting bronchodilators in COPD and the risk of adverse cardiovascular events
Samy Suissa et al.
EUROPEAN RESPIRATORY JOURNAL (2017)
Total management of chronic obstructive pulmonary disease (COPD) as an independent risk factor for cardiovascular disease
Katsuya Onishi
JOURNAL OF CARDIOLOGY (2017)
Efficacy and safety of long-acting beta-agonist/long-acting muscarinic antagonist combinations in COPD: a network meta-analysis
Yuji Oba et al.
THORAX (2016)
Serious Asthma Events with Fluticasone plus Salmeterol versus Fluticasone Alone
David A. Stempel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Serious Asthma Events with Budesonide plus Formoterol vs. Budesonide Alone
Stephen P. Peters et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD
Jadwiga A. Wedzicha et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Cardiac effects of current treatments of chronic obstructive pulmonary disease
Lies Lahousse et al.
LANCET RESPIRATORY MEDICINE (2016)
Electrocardiographic abnormalities and cardiac arrhythmias in chronic obstructive pulmonary disease
Christos A. Goudis et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2015)
Effect of once-daily indacaterol maleate/mometasone furoate on exacerbation risk in adolescent and adult asthma: a double-blind randomised controlled trial
Richard W. Beasley et al.
BMJ OPEN (2015)
Cardiovascular Safety of Long Acting Beta Agonist-Inhaled Corticosteroid Combination Products in Adult Patients with Asthma: A Systematic Review
Imran H. Iftikhar et al.
LUNG (2014)
Pooled safety analysis of the fixed-dose combination of indacaterol and glycopyrronium (QVA149), its monocomponents, and tiotropium versus placebo in COPD patients
Jadwiga A. Wedzicha et al.
RESPIRATORY MEDICINE (2014)
Heart failure and chronic obstructive pulmonary disease: the challenges facing physicians and health services
Nathaniel M. Hawkins et al.
EUROPEAN HEART JOURNAL (2013)
Pro-arrhythmic and pro-ischaemic effects of inhaled anticholinergic medications
Sonal Singh et al.
THORAX (2013)
Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study
Jadwiga A. Wedzicha et al.
LANCET RESPIRATORY MEDICINE (2013)
Unrecognised ventricular dysfunction in COPD
A. Macchia et al.
EUROPEAN RESPIRATORY JOURNAL (2012)
Cardiac effects of muscarinic receptor antagonists used for voiding dysfunction
Karl-Erik Andersson et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2011)